This document is the master engineering companion to the Christos™ Coherence Medicine Oncology Series (Papers 1–6). Where those papers present the clinical protocols, disease-specific applications, and scientific rationale for the Christos™ cancer device portfolio, the full companion document provides the complete engineering specifications required to take that portfolio from concept to manufactured product.
The Christos™ cancer device portfolio comprises seven device families covering all 50+ cancer types addressed in the Oncology Series, one universal active-therapy companion device (Frequency Sweep Wand), a programmable frequency generator platform, a complete healing fluid manufacturing library covering 20 formulations, and a comprehensive frequency library. Together these constitute a complete, manufacturable product ecosystem designed around one architectural principle: one electronic architecture, seven disease-specific expressions.
All seven device families share an identical electronic core — Nordic Semiconductor nRF52832 microcontroller, dual Analog Devices AD9833 DDS frequency generators, Texas Instruments LM386 amplifiers, BQ25570 battery management, and TCXO precision oscillator. Variation between families is limited to crystal type and arrangement, frequency set loaded in firmware, physical form factor dimensions, and body placement target. This modular design philosophy enables a manufacturer who qualifies one device family to produce all seven with minimal tooling changes.
The healing fluid library comprises 20 proprietary formulations — each named and referenced throughout the clinical papers of this series, each formulated for a specific cancer category, each incorporating evidence-based nutraceutical compounds and the Christos™ frequency-imprinting manufacturing protocol. Fluid formulas are proprietary and not disclosed in this public abstract. They are available to qualified manufacturing partners under executed non-disclosure agreements.
The regulatory pathway for all seven device families under the FDA General Wellness Policy is documented in full, enabling market entry within 3–6 months under wellness-only claims without premarket submission, with a defined upgrade pathway to 510(k) clearance as clinical evidence accumulates.
The Seven Device Families
The Healing Fluid Library
Twenty proprietary formulations are specified in the full companion document, each designed for a specific cancer category and referenced throughout Papers 1–6 of this series. Each fluid combines evidence-based nutraceutical compounds with the Christos™ frequency-imprinting manufacturing protocol.
| Fluid Name | Primary Cancer Application | Formula Status |
|---|---|---|
| MyeloFlux | Blood & Bone Marrow Cancers | Proprietary — available under NDA |
| PeritoFlux | Peritoneal Carcinomatosis | Proprietary — available under NDA |
| NeuroFlux (Cancer) | Brain & Neural Cancers | Proprietary — available under NDA |
| NeuroFlux (Memory) | Cognitive Decline | Proprietary — available under NDA |
| OsteoFlux | Bone Cancers & Metastases | Proprietary — available under NDA |
| MuscleFlux / SarcomaFlux | Soft Tissue Sarcomas / ASPS | Proprietary — available under NDA |
| PulmoLife | Lung & Pleural Cancers | Proprietary — available under NDA |
| HepatoFlux | Liver Cancer & Hepatic Metastases | Proprietary — available under NDA |
| PancreaFlux | Pancreatic Cancer | Proprietary — available under NDA |
| GastroFlux | Colorectal & Gastric Cancers | Proprietary — available under NDA |
| FeminaFlux | Ovarian, Uterine, Cervical Cancers | Proprietary — available under NDA |
| MasculFlux | Prostate Cancer | Proprietary — available under NDA |
| RenoFlux | Kidney & Bladder Cancers | Proprietary — available under NDA |
| LymphoFlux | Lymphoma & Lymphatic Support | Proprietary — available under NDA |
| DermoFlux | Breast Cancer & Melanoma | Proprietary — available under NDA |
| ThyroFlux / AdrenaFlux | Thyroid & Adrenal Cancers | Proprietary — available under NDA |
The Common Electronic Architecture
All seven device families share the following core architecture. This design decision enables a single manufacturer qualification process, one firmware codebase, and minimal tooling investment to bring the entire portfolio to production:
- Microcontroller: Nordic Semiconductor nRF52832 — ARM Cortex-M4, BLE 5.0, 512KB flash
- Frequency Generation: Dual Analog Devices AD9833 DDS chips — 0.001 Hz resolution, <0.1% THD, pure sine output
- Amplification: Texas Instruments LM386 — one per DDS channel; drives crystal node arrays
- Power Management: Texas Instruments BQ25570 — energy harvesting PMU with Li-Po charge management
- Reference Oscillator: 10 MHz TCXO — ±0.5 ppm; maintains frequency accuracy to ±0.001 Hz across battery discharge
- PCB Substrate: Flexible polyimide (Kapton), 0.2mm — conforms to body contours
- Encapsulant: Wacker Elastosil LR 3003/50 medical-grade silicone — ISO 10993 biocompatible
- IP Rating: IP68 (patches); IPX4 (NeuroBand) — waterproof for 24/7 continuous wear
- Regulatory Path: FDA General Wellness Policy — wellness claims; no premarket submission required
Frequency Library Overview
The Christos™ cancer device portfolio employs a 13-frequency library organized around the Solfeggio scale supplemented by specific neurological frequencies. All device-specific therapeutic mechanism claims are classified [HY] — hypothesis requiring experimental validation. The library includes: 174 Hz (foundation/inflammation), 285 Hz (tissue restoration), 396 Hz (liberation), 417 Hz (cleansing), 528 Hz (primary healing — present in all devices), 639 Hz (connection), 741 Hz (detoxification), 852 Hz (cellular awakening), 963 Hz (blueprint reset), 40 Hz (gamma — neurological), 7.83 Hz (Schumann resonance — chamber sessions), 2.5 Hz (delta — sleep support), and 6 Hz (theta — memory).
One architecture. Seven expressions. Fifty cancers. A complete manufacturing ecosystem — from the bone marrow of a myeloma patient to the hippocampus of someone losing their memory — governed by the same coherence principle and the same engineering platform.
Intellectual Property Status
All device names, system architectures, fluid formulations, frequency protocols, and manufacturing processes described in this document are the exclusive property of Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Publication of these abstracts establishes public prior art for all described device architectures and system designs. Commercial manufacturing of any device or fluid described in this series requires a valid executed licensing agreement.
The following are designated permanent trade secrets and are not disclosed in any public document: the 21 Core Generator equations of the MoR-144 Mathematical Framework and the Prediction Algorithm composition mechanics.
The Christos™ trademark is pending USPTO review. All product names referenced in this document are claimed trademarks.
Licensing and Manufacturing Partnership Inquiries
The Christos™ Cancer Device Portfolio is available for licensing under multiple structures — full portfolio license, single-family license, formula-only license, and white-label manufacturing partnerships.
All licensing discussions begin with execution of a mutual non-disclosure agreement. No formula, firmware, or detailed manufacturing documentation is shared before NDA is in place.
Target partners include: nutraceutical and supplement brands, medical device contract manufacturers, integrative oncology product companies, and academic research institutions seeking device licenses for clinical investigation.
Inquire About Licensing